FDA poised to go digital-first on drug safety labels—with paper as backup

What it does

This bill allows pharmaceutical manufacturers to provide prescribing information to doctors and pharmacists electronically instead of on paper, provided they offer the option to receive or request paper copies at no cost. The FDA must issue regulations within one year to implement this change and ensure healthcare professionals can still get paper copies if they want them, and must hold a public workshop within two years to discuss how to optimize the digital format.

Why we flagged it

The bill's core function is to amend FDA drug-labeling rules to permit digital-only prescribing information delivery, with a regulatory implementation timeline and stakeholder consultation requirement. It is a modernization of existing FDA authority, not a new subsidy or carve-out.

What the text implies

• Shifting the default from paper to digital may reduce prescriber awareness of critical safety information if digital systems are not universally accessible or if prescribers do not actively request paper copies.
• The bill requires manufacturers to provide paper copies 'without additional cost' on request, but does not specify response timelines or penalties for non-compliance, creating potential enforcement gaps.
• The FDA's obligation to 'minimize adverse economic impacts' on prescribers and dispensers may create pressure to weaken digital accessibility standards or delay implementation, potentially favoring manufacturers over user convenience.
• The public workshop requirement is advisory only and does not bind the FDA to adopt stakeholder recommendations, limiting transparency of how digital prescribing information will actually be optimized.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a genuine trade-off: it modernizes drug information delivery and may reduce costs and environmental waste, but it shifts the default from paper to digital, potentially disadvantaging prescribers and dispensers with limited digital access or those who prefer paper for safety-critical information. The opt-in paper provision protects against total exclusion, but the burden of requesting paper copies falls on users rather than manufacturers.

Who stands to gain

• pharmaceutical manufacturers (reduced printing and distribution costs)
• digital health information platforms and vendors (potential contracts to host or manage digital pres

Named in the bill

FDA, HHS Secretary, pharmaceutical manufacturers, prescribers, dispensers, Federal Food, Drug, and Cosmetic Act

Where it stands

1 cosponsor: 1 Democrats.

• Jun 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 11, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,557,670 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Markwayne Mullin, the sponsor, reported $979,756 in PAC receipts in the 2026 cycle. $0 of that came from 1 PAC tied to these lobbying clients.

• Sanofi Us Services Inc — $920,000 on 1 filing
• Astrazeneca Pharmaceuticals Lp — $670,000 on 1 filing
• Cencora, Inc. — $510,000 on 1 filing
• Viatris Inc — $360,000 on 1 filing
• Printing United Alliance — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.